INVO Bioscience (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® ...
News
- INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment ...
- Seattle Genetics: Q4 Earnings Snapshot - San Antonio Express-News
The biotechnology company posted revenue of $429.9 million in the period, beating Street forecasts. Eight analysts surveyed by Zacks expected ...
- SK Bioscience to develop COVID-19 Omicron-specific vaccine - Big News Network.com
As the Omicron COVID-19 variant which is now the most dominant strain in the world rapidly spread in Korea SK Bioscience also started developing ...
- 'Very over sold': Biotech brags about PhII Alzheimer's data, but experts are underwhelmed ...
Alzheon, a little biotech developing an oral amyloid-clearing tablet, ... the neurobiology chair at the University of Texas at San Antonio, ...
- 1819 Innovation Hub tenant inks key partnership with Korea VC firm - The Business Journals
A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration since planting ...